Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
NITROPRUSSIDE-EMC (Emcure Pharmaceuticals Pty Ltd)
Product name
NITROPRUSSIDE-EMC
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
130 working days (255)
Active ingredients
sodium nitroprusside
Registration type
New generic medicine
Indication
NITROPRUSSIDE-EMC (concentrated solution for injection) is indicated for:
- Immediate reduction of blood pressure in patients with hypertensive crises. Concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.
- Producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.
- Short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. Patients should be commenced on oral therapy as soon as possible.